RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical
activity of RRx-001 administered in combination with irinotecan.
RRx-001 is associated with resensitization to irinotecan in tumors that are previously
refractory. This effect has been attributed to the ability of RRx-001 to restore the
expression of aberrantly silenced genes, thus re-establishing pathway functions. However,
resensitization may have more than one mechanism, among them Pgp pump inhibition and vascular
modulation, leading to improved penetration of standard chemotherapy.